AzTrials
AzTrials

Neurogenic Orthostatic HypotensionNCT04976101

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

A study testing Sinosuidal Galvanic Vestibular Stimulation in people with Neurogenic Orthostatic Hypotension, run by Hackensack Meridian Health at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Neurogenic orthostatic hypotension occurs in a significant number of people and has no effective treatment. Neurogenic orthostatic hypotension is associated with intermittent episodes of fainting which can be debilitating for the patients. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Neurogenic Orthostatic Hypotension
What is being tested?
Sinosuidal Galvanic Vestibular Stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited States
Study dates
1 Jan 2023to 15 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient with unexpected intermittent syncope or a positive tilt test

Who cannot join

  • Syncope cannot be related to significant heart disease
  • cannot be not be related to serious medical illnesses that cause increased susceptibility to fainting, such as in Parkinson's Disease
  • Pregnant or lactating women

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Hackensack Univeristy Medical Center

    Hackensack, New Jersey, 07601

Other trials in United States

About this study

Official title: A Pilot Study to Assess Sinusoidal Galvanic Vestibular Stimulation in Neurogenic Orthostatic Hypotension

Neurogenic orthostatic hypotension occurs in a significant number of people and has no effective treatment. Neurogenic orthostatic hypotension is associated with intermittent episodes of fainting which can be debilitating for the patients. Using sinusoidal galvanic vestibular stimulation, an oscillating current between the two ears, collaborators have discovered an effective technique to habituate anesthetized rats that develop vasovagal responses. The investigators propose to determine whether a similar use of sinusoidal galvanic vestibular stimulation can eliminate or alleviate neurogenic orthostatic hypotension and the associated syncope in susceptible human subjects. If so, then sinusoidal galvanic vestibular stimulation, which is safe and widely used to study muscle sympathetic nerve activity, can be used in humans, who have a history of syncope and a positive tilt test to habituate vasovagal responses. Habituation will be accomplished using repetitive periods of sinusoidal galvanic vestibular stimulation in two 30min sessions three times/week for 2 weeks. Similar 1 hour sessions are routinely used by others when activating muscle sympathetic nerve activity with sinusoidal galvanic vestibular stimulation without harm to the subjects. The 30 min periods were chosen because this was effective in producing habituation of vasovagal responses. The habituating stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency bipolar, ± 2 mA, 0.025 Hz oscillating current sinusoidal galvanic vestibular stimulation between the mastoids. Subjects will be seated during the stimulation. The onset and end of the stimulation period will be denoted by tones, and the subjects will be free to watch television, read, or listen to music while they are being stimulated. The effectiveness of the habituation will be determined in several ways: 1) Subjects will keep a history of the number of episodes of syncope in the inter-test intervals. 2) They will have tilt tests at the beginning and end of habituation. 3) Their blood pressure and heart rate will be recorded and the investigators will determine if there is a loss of low frequency (0.025 Hz) oscillations, which the investigators have found in animal models to disappear when the animals are habituated. 4) Habituation should be accompanied by an increase in heart rate to counteract the fall in blood pressure.

Read the detailed description

Syncope is a highly prevalent condition affecting 42% of the population at some point in life. Physical injury occurs with syncopal events and the danger of injury becomes more prevalent with age. Syncope accounts for 3% of visits to emergency departments and 6% of all admissions to hospitals. For patients with frequent recurrent syncope, psychosocial impairment has an estimated adverse impact on 33% of the assessed aspects of daily life. There is also a large economic impact, with an estimated $2.4 billion annual cost, mostly due to hospitalizations.

Neurogenic orthostatic hypotension (nOH) results from impaired arterial vasoconstriction that normally is mediated by the baroreflex in response to gravitational pooling of blood. The characteristic findings in nOH are a drop in systolic blood pressure (SBP) of 20 mmHg or more, or a drop in diastolic blood pressure (DBP) of 10 mmHg or more, in response to standing or head-up tilt. What distinguishes nOH from other causes of orthostatic hypotension, such as vasovagal syncope or dehydration, is a blunted compensatory heart rate increase (<15 BPM). nOH accounts for 15% of syncope in the general population and 24% of such cases in emergency room setting. The autonomic failure that precipitates nOH may result from α-synuclein protein deposits in central glial cells (multiple system atrophy) or in postganglionic autonomic neurons when associated with Parkinson's disease or primary autonomic failure. Secondary causes of autonomic failure include diabetic neuropathy and other autoimmune conditions that selectively target the peripheral autonomic nerves.

There is currently no standard of care for people suffering from syncope. Several treatment options have been explored, including beta blockers, corticosteroids, and pacemakers, but none of these have been more effective than placebo. The most promising therapy to date has been repeated static head-up tilts. Vestibulo-sympathetic reflex (VSR) is a term used for the redistribution of blood by vestibular stimulation through the actions of the sympathetic nervous system. 60° static head-up tilt activates otolith and body tilt receptors, which produce cardiovascular changes through the VSR. Using repeated static head-up tilts, "syncope-sensitive" patients were repetitively tilted 60° for periods of time. This was shown to habituate the (VSR) and reduce or eliminate syncope in some cases. However, while it was possible to habituate some subjects with head-tilts, the habituation techniques were too tedious and impractical to be effective in the general population. If there were a less tedious procedure that activated the vestibular system, it could be used to habituate syncope through the VSR.

Sinusoidal galvanic vestibular stimulation (sGVS) activates the otolith system. Blood pressure (BP) and heart rate (HR) have been studied in vasovagal responses in isoflurane-anesthetized Long-Evans rats during sinusoidal galvanic vestibular stimulation (sGVS) and nose-up tilt. In these studies, susceptible rats developed synchronous ≈20-50 mmHg decreases in BP and ≈20-50 bpm decreases in HR over seconds that recovered slowly over minutes in response to repeated vestibular (otolith) stimulation. The sudden decrease in BP and HR, followed by the slower return to pre-stimulus values, are the main components of the vasovagal response that underlie and generate vasovagal syncope. It was found that rats previously susceptible to the induction of vasovagal responses progressively lost their susceptibility as testing continued. The loss of susceptibility to vasovagal responses indicates that the rats were habituated through activation of the VSR, using sGVS. It was concluded that habituation was successful by blocking the occurrence of low frequency oscillations in BP and HR in rats, which are thought to be the critical elements in initiating vasovagal responses. The loss of susceptibility in this study was associated with a rise in HR to oppose the fall in BP. These findings concurred with previous studies demonstrating habituated responses with static head-up tilts. Why these findings were not supported by some other studies, remains unclear; but one author suggested the reason for their findings in humans was that static head-up tilts were sufficiently tedious that it resulted in non-compliance.

The strategy for addressing nOH should likely focus on raising BP rather than HR as a fall in BP is the defining feature of this condition. Studies of the VSR have been performed in rats without identified vasovagal responses. Yakushin and colleagues applied linear acceleration in anesthetized rats and found increases in BP that were maximal during upward and forward translation [36]. HR was unaffected by single translations, but oscillations may influence it more gradually.

There are challenges in the study of various populations affected by syncope. The most common condition, vasovagal syncope may be difficult to objectively diagnose due to the intermittent nature of the symptoms. In particular, many patients have normal tilt testing in the laboratory setting and are only symptomatic during times of physical or emotional stress. A more easily diagnosed condition, postural orthostatic tachycardia syndrome, is far less common and patients frequently improve spontaneously after adolescence.

This study will focus on syncope caused by nOH because there is a larger population of potential subjects and laboratory testing is more reliable. It is our hypothesis that sinusoidal galvanic vestibular stimulation (sGVS) can be used to produce habituation of syncope in humans. sGVS has been used to activate muscle sympathetic nerve activity (MSNA) without side-effects beyond motion-sickness in a few test subjects. During habituation periods, subjects are able to read, listen to music, and watch TV, etc.

Being tested
Sinosuidal Galvanic Vestibular Stimulation, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sinosuidal Galvanic Vestibular StimulationDevice

    stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids

  • PlaceboDevice

    When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)

Study groups in NCT04976101
Study groupRoleWhat they receive
Sinusoidal Galvanic Vestibular StimulationExperimentalTreatment: 1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz.
Receives: Device: Sinosuidal Galvanic Vestibular Stimulation
PlaceboPlacebo comparatorTreatment: 1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz.
Receives: Device: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Net change in blood pressure during head-up tilt

    Blood pressure is measured during a head up tilt test and recorded

    Measured: 1 week prior vs 1 week after treatment

  2. Net change in heart rate during head-up tilt

    Heart rate is measured during a head up tilt test and recorded

    Measured: 1 week prior vs 1 week after treatment

Secondary outcomes (4)
  1. Gain of baroreceptor sensitivity

    Gain of baroreceptor sensitivity

    Measured: 1 week prior vs 1 week after treatment

  2. Phase of baroreceptor sensitivity

    Phase of baroreceptor sensitivity

    Measured: 1 week prior vs 1 week after treatment

  3. Change in frequency of syncope in the week prior vs week after treatment

    Measuring change in frequency of syncope in the week prior vs week after treatment

    Measured: 1 week prior vs 1 week after treatment

  4. Change in frequency of low frequency oscillations in blood pressure and heart rate during tilt testing

    Measuring the change in frequency of low frequency oscillations in blood pressure and heart rate during tilt testing

    Measured: 1 week prior vs 1 week after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2021
  2. Study start1 Jan 2023 (estimated)
  3. Primary completion15 Feb 2025 (estimated)
  4. Study completion15 Feb 2025 (estimated)

Why it stopped: It never enrolled any patients

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04976101
Sponsor's protocol ID
Pro2020-0755
Status last verified
Dec 2022
First submitted
9 Jul 2021
Last updated
16 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • da Silva RM. Syncope: epidemiology, etiology, and prognosis. Front Physiol. 2014 Dec 8;5:471. doi: 10.3389/fphys.2014.00471. eCollection 2014.

    PubMed 25538626
  • Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS); Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Ruiz Granell R, Sarasin F, Ungar A, van Dijk JG, Walma EP, Wieling W. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009 Nov;30(21):2631-71. doi: 10.1093/eurheartj/ehp298. Epub 2009 Aug 27. No abstract available.

    PubMed 19713422
  • Grubb BP. Clinical practice. Neurocardiogenic syncope. N Engl J Med. 2005 Mar 10;352(10):1004-10. doi: 10.1056/NEJMcp042601. No abstract available.

    PubMed 15758011
  • Sun BC. Quality-of-life, health service use, and costs associated with syncope. Prog Cardiovasc Dis. 2013 Jan-Feb;55(4):370-5. doi: 10.1016/j.pcad.2012.10.009.

    PubMed 23472773
  • Arnold AC, Ng J, Lei L, Raj SR. Autonomic Dysfunction in Cardiology: Pathophysiology, Investigation, and Management. Can J Cardiol. 2017 Dec;33(12):1524-1534. doi: 10.1016/j.cjca.2017.09.008. Epub 2017 Sep 14.

    PubMed 29102451
  • Sarasin FP, Louis-Simonet M, Carballo D, Slama S, Junod AF, Unger PF. Prevalence of orthostatic hypotension among patients presenting with syncope in the ED. Am J Emerg Med. 2002 Oct;20(6):497-501. doi: 10.1053/ajem.2002.34964.

    PubMed 12369019
  • Calkins H. Pharmacologic approaches to therapy for vasovagal syncope. Am J Cardiol. 1999 Oct 21;84(8A):20Q-25Q. doi: 10.1016/s0002-9149(99)00626-8.

    PubMed 10568557
  • Cohen B, Martinelli GP, Xiang Y, Raphan T, Yakushin SB. Vestibular Activation Habituates the Vasovagal Response in the Rat. Front Neurol. 2017 Mar 15;8:83. doi: 10.3389/fneur.2017.00083. eCollection 2017.

    PubMed 28360882
  • Sheldon R, Connolly S; Vasovagal Pacemaker Study II. Second Vasovagal Pacemaker Study (VPS II): rationale, design, results, and implications for practice and future clinical trials. Card Electrophysiol Rev. 2003 Dec;7(4):411-5. doi: 10.1023/B:CEPR.0000023157.37745.76.

    PubMed 15071266
  • Yates BJ, Bolton PS, Macefield VG. Vestibulo-sympathetic responses. Compr Physiol. 2014 Apr;4(2):851-87. doi: 10.1002/cphy.c130041.

    PubMed 24715571
  • Yates BJ, Holmes MJ, Jian BJ; New Collective Author. Adaptive plasticity in vestibular influences on cardiovascular control. Brain Res Bull. 2000 Sep 1;53(1):3-9. doi: 10.1016/s0361-9230(00)00302-6.

    PubMed 11033202
  • Mittelstaedt H. Origin and processing of postural information. Neurosci Biobehav Rev. 1998 Jul;22(4):473-8. doi: 10.1016/s0149-7634(97)00032-8.

    PubMed 9595557
  • Mittelstaedt H. Somatic graviception. Biol Psychol. 1996 Jan 5;42(1-2):53-74. doi: 10.1016/0301-0511(95)05146-5.

    PubMed 8770370
  • Yates BJ, Miller AD. Properties of sympathetic reflexes elicited by natural vestibular stimulation: implications for cardiovascular control. J Neurophysiol. 1994 Jun;71(6):2087-92. doi: 10.1152/jn.1994.71.6.2087.

    PubMed 7931504
  • Cohen B, Yakushin SB, Holstein GR. What does galvanic vestibular stimulation actually activate: response. Front Neurol. 2012 Oct 22;3:148. doi: 10.3389/fneur.2012.00148. eCollection 2012. No abstract available.

    PubMed 23093948

Questions about this trial

What is this clinical trial studying?

A study testing Sinosuidal Galvanic Vestibular Stimulation in people with Neurogenic Orthostatic Hypotension, run by Hackensack Meridian Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 16 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Net change in blood pressure during head-up tilt (time frame: 1 week prior vs 1 week after treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04976101, which also lists 43 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in